Ginkgo Bioworks Holdings Return on Tangible Equity 2020-2022 | DNA

Current and historical return on tangible equity values for Ginkgo Bioworks Holdings (DNA) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Ginkgo Bioworks Holdings Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-03-31 $-2.35B $1.57B -200.68%
2021-12-31 $-1.83B $1.52B -235.27%
2021-06-30 $-0.21B $0.01B -8280.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.228B $0.314B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00